Safety, Tolerability, Extended Early Bactericidal Activity and PK of Higher Doses Rifampicin in Adults With Pulmonary TB (HR1)

Study Director
Start Date
6 / 2011
Trial Phase
Phase II
Trial Status
Current Enrollment
Target Enrollment

From Clinical 11 March 2017:  The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.  Verified June 2014 by Radboud University.Recruitment status was:  Active, not recruiting

A dose-ranging trial to optimize the dose of rifampin in the treatment of tuberculosis. Boeree MJ, Diacon AH, Dawson R, Narunsky K, du Bois J, Venter A, Phillips PP, Gillespie SH, McHugh TD, Hoelscher M, Heinrich N, Rehal S, van Soolingen D, van Ingen J, Magis-Escurra C, Burger D, Plemper van Balen G, Aarnoutse RE; PanACEA Consortium. Am J Respir Crit Care Med. 2015 May 1;191(9):1058-65.

Sponsor: Radboud University
Collaborators: European and Developing Countries Clinical Trials Partnership (EDCTP)
Department of Clinical Pharmacy, University Medical Centre St Radboud, The Netherlands.
University Centre for Chronic Diseases Dekkerswald, Groesbeek, NL
Information provided by (Responsible Party):
Radboud University
Study Chair: Martin Boeree, MD, PhD Radboud university medical center, University Centre for Chronic Deseases Dekkerswald
Study Chair: Rob Aarnoutse, PharmD, PhD Radboud University
Principal Investigator: Andreas Diacon, MD Task Applied Science
Principal Investigator: Rodney Dawson, MD

University of Cape Town Lung Institute

Compound Associations